Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$84.69M$84.69M+6.1% vs Q1 2019 Net Income$3.95M$3.95M+355.0% vs Q1 2019 EPS Diluted$0.08$0.08+300.0% vs Q1 2019 Gross Profit$36,823,000+19.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$1,477,000N/M Free Cash Flowderived-$6,529,000N/M Margins · derivedGross margin43.5%+4.8 pt vs Q1 2019
Operating margin8.8%+12.8 pt vs Q1 2019
Net margin4.7%+3.6 pt vs Q1 2019
ended Mar 31, 2020 · filed May 11, 2020 · 41 d after period end